Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Pioglitazone418 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A10728 | 31219486 | Saudi Med J | Position statement on the diagnosis and management of non-alcoholic fatty liver disease. | 2019 | Details |
| A10804 | 31182918 | Int J Biol Sci | A Comprehensive Study of High Cholesterol Diet-Induced Larval Zebrafish Model: A Short-Time In Vivo Screening Method for Non-Alcoholic Fatty Liver Disease Drugs. | 2019 | Details |
| A10813 | 31176759 | Mol Cell Endocrinol | Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet. | 2019 | Details |
| A10869 | 31149341 | Pharmacol Res Perspect | A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH). | 2019 | Details |
| A10891 | 31137547 | Medicina (Kaunas) | Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10893 | 31136997 | Top Antivir Med | Fatty liver disease in persons with HIV infection. | 2019 | Details |
| A10999 | 31085617 | Postgrad Med J | Diagnosis and management of non-alcoholic fatty liver disease. | 2019 | Details |
| A11212 | 30993937 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. | 2019 | Details |
| A11279 | 30961499 | Curr Vasc Pharmacol | Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. | 2020 | Details |
| A11310 | 30945129 | Curr Obes Rep | Nonalcoholic Fatty Liver Disease and Obesity Treatment. | 2019 | Details |
| A11319 | 30940296 | Gene Expr | Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. | 2019 | Details |
| A11365 | 30920975 | Eur J Gastroenterol Hepatol | Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. | 2019 | Details |
| A11532 | 30854694 | Aliment Pharmacol Ther | Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. | 2019 | Details |
| A11557 | 30841472 | Biomed Pharmacother | Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. | 2019 | Details |
| A11561 | 30839326 | Am J Gastroenterol | Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. | 2019 | Details |
| A11697 | 30788048 | World J Diabetes | SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. | 2019 | Details |
| A12020 | 30641706 | Diabetes Metab Syndr | Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study. | 2018 | Details |
| A12244 | 30549292 | Hepatology | Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. | 2019 | Details |
| A12251 | 30547370 | Pharmacoeconomics | Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. | 2019 | Details |
| A12377 | 30479664 | Therap Adv Gastroenterol | Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. | 2018 | Details |
| A12419 | 30462610 | Horm Mol Biol Clin Investig | The impact of steatosis on liver regeneration. | 2018 | Details |
| A12421 | 30460863 | Pharm Biol | Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus. | 2018 | Details |
| A12474 | 30431378 | Curr Med Res Opin | Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. | 2018 | Details |
| A12479 | 30430467 | Pharmacoeconomics | Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. | 2019 | Details |
| A12499 | 30420265 | Arab J Gastroenterol | Managing diabetes and liver disease association. | 2018 | Details |
| A12521 | 30411635 | Expert Opin Pharmacother | Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. | 2018 | Details |
| A12615 | 30363699 | PPAR Res | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression. | 2018 | Details |
| A12660 | 30341231 | Postgrad Med J | Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | 2018 | Details |
| A12758 | 30299993 | Expert Opin Pharmacother | Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. | 2018 | Details |
| A12788 | 30287791 | Int J Mol Sci | Identification of a Novel PPAR-γ Agonist through a Scaffold Tuning Approach. | 2018 | Details |
| A12830 | 30264828 | AIDS Rev | Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection | 2018 | Details |
| A13132 | 30122876 | World J Gastroenterol | Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. | 2018 | Details |
| A13228 | 30074500 | Curr Opin Endocrinol Diabetes Obes | Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. | 2018 | Details |
| A13229 | 30073778 | J Diabetes | Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. | 2018 | Details |
| A13247 | 30065651 | Front Pharmacol | A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. | 2018 | Details |
| A13250 | 30064623 | Ugeskr Laeger | [Treatment of non-alcoholic fatty liver disease]. | 2018 | Details |
| A13412 | 29990865 | Biomed Pharmacother | Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway. | 2018 | Details |
| A13453 | 29964161 | Pharmacol Res | Human-based systems: Mechanistic NASH modelling just around the corner? | 2018 | Details |
| A13643 | 29858843 | Hormones (Athens) | The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). | 2018 | Details |
| A13990 | 29655574 | Rev Gastroenterol Mex (Engl Ed) | Current treatment for non-alcoholic fatty liver disease. | 2018 | Details |
| A14003 | 29643297 | J Vet Med Sci | Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model. | 2018 | Details |
| A14013 | 29634314 | Am J Physiol Endocrinol Metab | Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. | 2018 | Details |
| A14097 | 29589386 | Endocrinol Metab (Seoul) | Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14234 | 29512720 | Mol Med Rep | Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver. | 2018 | Details |
| A14394 | 29428719 | Biochem Biophys Res Commun | Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. | 2018 | Details |
| A14500 | 29379801 | J Diabetes Res | Quercetin Improves Glucose and Lipid Metabolism of Diabetic Rats: Involvement of Akt Signaling and SIRT1. | 2017 | Details |
| A14596 | 29333610 | Aliment Pharmacol Ther | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. | 2018 | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | 2017 | Details |
| A14808 | 29223443 | Clin Gastroenterol Hepatol | Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. | 2017 | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017 | Details |
| A14940 | 29164820 | Liver Int | Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. | 2017 | Details |
| A14978 | 29146119 | Diabetes Res Clin Pract | An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. | 2017 | Details |
| A15014 | 29128055 | Clin Liver Dis | Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15074 | 29108191 | Zhonghua Gan Zang Bing Za Zhi | [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017]. | 2017 | Details |
| A15082 | 29106066 | J Dig Dis | Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. | 2017 | Details |
| A15101 | 29095942 | PLoS One | Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. | 2017 | Details |
| A15254 | 29023319 | Eur J Gastroenterol Hepatol | Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. | 2017 | Details |
| A15361 | 28946547 | Cancer Biomark | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. | 2017 | Details |
| A15429 | 28918389 | J Investig Med | Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. | 2017 | Details |
| A15467 | 28892924 | J Clin Diagn Res | Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats. | 2017 | Details |
| A15582 | 28831172 | Sci Rep | Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis. | 2017 | Details |
| A15703 | 28751548 | Diabetes Care | Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. | 2017 | Details |
| A15777 | 28714405 | Curr Pharm Des | Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter. | 2017 | Details |
| A15798 | 28705172 | BMC Endocr Disord | Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. | 2017 | Details |
| A15862 | 28677333 | Aliment Pharmacol Ther | Review article: new treatments in non-alcoholic fatty liver disease. | 2017 | Details |
| A15875 | 28676020 | Curr Vasc Pharmacol | Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. | 2018 | Details |
| A15876 | 28676019 | Curr Vasc Pharmacol | Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. | 2018 | Details |
| A15877 | 28676018 | Curr Vasc Pharmacol | Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? | 2018 | Details |
| A15946 | 28641031 | Expert Opin Drug Saf | Treatment options for nonalcoholic steatohepatitis - a safety evaluation. | 2017 | Details |
| A16016 | 28611274 | Ann Hepatol | Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. | 2018 | Details |
| A16076 | 28581362 | Future Cardiol | PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. | 2017 | Details |
| A16092 | 28575232 | J Clin Endocrinol Metab | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. | 2017 | Details |
| A16175 | 28521870 | Metabolism | The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. | 2017 | Details |
| A16234 | 28494529 | Clin Mol Hepatol | NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. | 2017 | Details |
| A16288 | 28470881 | Aliment Pharmacol Ther | Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. | 2017 | Details |
| A16420 | 28404113 | Lancet Gastroenterol Hepatol | Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. | 2016 | Details |
| A16515 | 28346237 | Curr Opin Gastroenterol | Current and future pharmacologic treatment of nonalcoholic steatohepatitis. | 2017 | Details |
| A16627 | 28276821 | Expert Rev Gastroenterol Hepatol | Current and future treatment options in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A16628 | 28276774 | Expert Rev Clin Pharmacol | Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. | 2017 | Details |
| A16692 | 28241279 | JAMA Intern Med | Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. | 2017 | Details |
| A16774 | 28185715 | Clin Ther | Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16925 | 28089623 | Dig Liver Dis | Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? | 2016 | Details |
| A17004 | 28052626 | Liver Int | Therapies in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17056 | 28019064 | Hepatol Res | Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. | 2017 | Details |
| A17111 | 27986466 | Trends Endocrinol Metab | Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. | 2016 | Details |
| A17364 | 27823604 | Endocrinol Metab Clin North Am | Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. | 2016 | Details |
| A17519 | 27759627 | Medicine (Baltimore) | Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. | 2016 | Details |
| A17595 | 27727520 | Liver Int | The therapeutic landscape of non-alcoholic steatohepatitis. | 2016 | Details |
| A17655 | 29416297 | Hippokratia | The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease. | 2020 | Details |
| A17690 | 27656480 | J Clin Diagn Res | Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease. | 2016 | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | 2016 | Details |
| A17878 | 27506737 | Metabolism | Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. | 2016 | Details |
| A18105 | 27349145 | Eur J Pharmacol | Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD). | 2016 | Details |
| A18144 | 27322798 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | 2016 | Details |
| A18188 | 27301803 | Metabolism | Pharmacological management of nonalcoholic fatty liver disease. | 2016 | Details |
| A18220 | 27277347 | Mymensingh Med J | Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients. | 2016 | Details |
| A18484 | 27101131 | Diabetologia | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. | 2016 | Details |
| A18554 | 28702244 | Clin Diabetes Endocrinol | Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. | 2016 | Details |
| A18570 | 27053232 | Diabetologia | EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? | 2016 | Details |
| A18661 | 27006654 | Gastroenterol Res Pract | A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. | 2016 | Details |